• 1. An approach to the structure and vibrational analysis of cis- and trans-3-chlorostyrene through IR/Raman and INS spectroscopies and theoretical ab initio/DFT calculations?
  J. M. Granadino-Roldán,M. Fernández-Gómez,A. Navarro,T. Pe?a Ruiz,U. A. Jayasooriya Phys. Chem. Chem. Phys., 2004,6, 1133-1143
• 2. An inter-tangled network of redox-active and conducting polymers as a cathode for ultrafast rechargeable batteries
  Jieun Kim,Han-Saem Park,Tae-Hee Kim,Sung Yeol Kim,Hyun-Kon Song Phys. Chem. Chem. Phys., 2014,16, 5295-5300
• 3. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 4. Aggregation-induced emission based on a fluorinated macrocycle: visualizing spontaneous and ultrafast solid-state molecular motions at room temperature via F?F interactions?
  Mei Zhang,Jingjing Guo,Tingting Liu,Zhanyu He,Majeed Irfan,Zujin Zhao,Zhuo Zeng J. Mater. Chem. C, 2020,8, 14919-14924
• 5. Alumina coating on 5 V lithium cobalt fluorophosphate cathode material for lithium secondary batteries – synthesis and electrochemical properties?
  S. Amaresh,K. Karthikeyan,K. J. Kim,Y. S. Lee RSC Adv., 2014,4, 23107-23115

Research Brief on 3-Amino-1-(2-methylpropyl)cyclobutane-1-carboxylic acid (CAS: 2228775-76-4)

The compound 3-Amino-1-(2-methylpropyl)cyclobutane-1-carboxylic acid (CAS: 2228775-76-4) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its unique structural properties and potential therapeutic applications. This research brief synthesizes the latest findings on this compound, focusing on its synthesis, biological activity, and relevance in drug discovery.

Recent studies have highlighted the role of 3-Amino-1-(2-methylpropyl)cyclobutane-1-carboxylic acid as a versatile building block in the synthesis of novel peptide mimetics and small-molecule inhibitors. The cyclobutane ring, coupled with the amino and carboxylic acid functional groups, provides a rigid scaffold that can be exploited for the design of conformationally constrained bioactive molecules. Researchers have successfully incorporated this compound into peptidomimetics targeting protease enzymes, demonstrating enhanced binding affinity and metabolic stability compared to linear peptides.

In a 2023 study published in the Journal of Medicinal Chemistry, the compound was utilized as a key intermediate in the development of selective inhibitors for a class of metalloproteinases implicated in cancer metastasis. The research team employed a structure-based drug design approach, leveraging the constrained geometry of the cyclobutane ring to optimize interactions with the enzyme's active site. The resulting inhibitors exhibited nanomolar potency and improved pharmacokinetic profiles in preclinical models.

Another significant application of 3-Amino-1-(2-methylpropyl)cyclobutane-1-carboxylic acid has been in the field of central nervous system (CNS) drug discovery. Its ability to cross the blood-brain barrier, attributed to the lipophilic 2-methylpropyl substituent, has made it an attractive scaffold for designing neuromodulators. Recent work has explored its incorporation into GABA analogues, with promising results in animal models of epilepsy and neuropathic pain.

The synthetic accessibility of this compound has also been a focus of recent research. A 2024 publication in Organic Letters described an efficient asymmetric synthesis route that achieves high enantiomeric purity, addressing previous challenges in obtaining the compound in optically active form. This advancement is particularly important given the increasing recognition of the significance of chirality in drug-receptor interactions.

From a safety and toxicology perspective, preliminary studies indicate that 3-Amino-1-(2-methylpropyl)cyclobutane-1-carboxylic acid exhibits favorable in vitro safety profiles, with no significant cytotoxicity observed in standard assays. However, comprehensive in vivo toxicology studies are still needed to fully evaluate its potential for clinical development.

In conclusion, 3-Amino-1-(2-methylpropyl)cyclobutane-1-carboxylic acid represents a promising scaffold in medicinal chemistry with diverse applications. Its unique structural features offer opportunities for the design of novel therapeutics across multiple disease areas. Continued research into its structure-activity relationships and optimization of derivatives will likely yield important contributions to drug discovery in the coming years.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)